Atlanta 2/27/2014 4:00:00 AM
News / Stocks

MissionIR News - VistaGen Therapeutics (VSTA) Tackling Expensive Problem of Drug Failure with Human Clinical Trials in a Test Tube

MissionIR would like to highlight VistaGen Therapeutics, Inc. (OTCQB: VSTA), a biotechnology company, focused on applying proprietary human pluripotent stem cell technology for drug rescue and cell therapy. Its Human Clinical Trials in a Test Tube is a pluripotent stem cell technology platform for predictive toxicology, drug development, and drug rescue.

In the company’s news,

VistaGen Therapeutics continues to address the growing industry problem of drug candidate failure. With diseases such as Alzheimer’s, type 2 diabetes, and rheumatoid arthritis on the rise, there is a growing need for new and more effective treatments. But as an editorial by the Washington Post on new drug development initiatives by the National Institutes of Health makes clear, the cost of drug development failure is staggering—and widespread. According to the editorial, “taking a drug candidate from early discovery through Food and Drug Administration approval takes a decade and has a 95 percent failure rate.” Plus, with the cost of drug development being known to be able to exceed $1 billion, it is clear that pharmaceutical companies face a very uphill challenge in bringing blockbuster, high-therapeutic-potential drugs to market in today’s “drug approval climate”.

VistaGen Therapeutics, a California-based biotechnology company, meets this problem head-on with its Human Clinical Trials in a Test Tube™, a human pluripotent stem cell technology that enables biotechnology and pharmaceutical companies to identify unexpected heart or liver safety concerns before a drug candidate has journeyed far into its development process. With this “drug rescue” capability, biotechnology and pharmaceutical companies also become able to renew their bring-to-approval efforts of once-promising-but-now-backshelved drug candidates that were discontinued due to heart or liver safety issues.

According to a Forbes article in 2012, the sunk cost of a failed drug candidate for a big pharmaceutical company can be huge. The article notes that the cost of an average drug developed by a major pharmaceutical company is at least $4 billion. That is where the drug rescue potential of VistaGen Therapeutics’ technology becomes clear. VistaGen Therapeutics believes that conventionally used toxicological testing systems, such as animal testing and other nonclinical methods, do not closely approximate human biology enough to account for initially undetected liver and heart toxicity and metabolism issues. Human Clinical Trials in a Test Tube™, in contrast, enables the differentiation of human pluripotent stem cells into mature human cells. With these resources in hand, therapeutic solution developers then become able to identify any emerging liver or heart safety issues before a drug candidate has generated huge sunk costs in research and development.

Mr. Shawn Singh, J.D., Chief Executive Officer of VistaGen Therapeutics, has described the disruptive potential of Human Clinical Trials in a Test Tube™ as “game-changing”. Having noted that he has not seen anything like the ways VistaGen Therapeutics is applying stem cell technology in his broad professional career, Mr. Singh has signified his confidence that the human pluripotent stem cell technology could change the face—and cost dynamics—of American drug development and approval.

About MissionIR

MissionIR is committed to connecting the investment community with companies that have great potential and a strong dedication to building shareholder value. We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices.

To sign up for The MissionIR Report, please visit

To connect with MissionIR via Facebook, please visit

To connect with MissionIR via Twitter, please visit

Please read FULL disclaimer on the MissionIR website:

Forward-Looking Statement:

This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.